# Fractyl Health Faces Investor Scrutiny After Study Disclosures and Stock Fall

- URL: https://stocks.freetheai.org/news/fractyl-health-faces-investor-scrutiny-after-study-disclosures-and-stock-fall-934f1d
- Published: 2026-10-19T23:18:00Z
- Category: company_news; sentiment: bearish; impact: high
- Symbols: [NASDAQ:GUTS](https://stocks.freetheai.org/symbols/NASDAQ-GUTS)
- Written by our AI from expert market sources across the web for FreeTheAI Stocks, built by Vibhek Soni
- How write-ups are made: https://stocks.freetheai.org/how-we-write
- Not financial advice: https://stocks.freetheai.org/disclaimer

Fractyl Health, Inc. (NASDAQ:GUTS) is under investor scrutiny following disclosures regarding its REMAIN-1 Midpoint Cohort evaluating Revita for weight maintenance after stopping GLP-1 therapy. Data showed Revita-treated patients regained 4.5% of their weight versus 7.5% for the sham group, while management noted the cohort lacked statistical power for efficacy analysis.

Management later disclosed that higher-than-expected weight regain at a single trial site significantly impacted overall results, attributing the issue to weaker diet and lifestyle counseling. The news triggered immediate market reaction, sending shares down 68.03% to $0.585 on January 29, 2026. Following an analyst downgrade from Morgan Stanley lowering its target price from $8.00 to $2.00, the stock fell another 21.37% the following day to close at $0.46.

With shares currently trading down 10.97% today at $1.38, investors continue to monitor corporate governance and legal developments surrounding the trial disclosures and subsequent financial loss.

## Key points

- Fractyl Health reported six-month REMAIN-1 trial data showing a 4.5% weight regain for Revita patients compared to 7.5% for the sham group.
- Management revealed a single study site with higher weight regain materially distorted overall trial results due to inconsistent lifestyle counseling.
- Morgan Stanley downgraded Fractyl stock and reduced its price target from $8.00 to $2.00 following the announcement.
- Fractyl Health shares dropped over 68% on January 29, 2026, and currently trade at $1.38 after falling 10.97% today.

## Questions and answers

### Why did Fractyl Health stock drop in January 2026?

Fractyl Health shares fell 68.03% on January 29, 2026, after reporting trial data for Revita where higher-than-expected weight regain at a single study site materially impacted results. Management noted the trial cohort was not powered for efficacy analysis.

### What were the results of Fractyl Health's REMAIN-1 study?

In the six-month REMAIN-1 cohort, Revita-treated patients experienced a 4.5% weight regain after stopping GLP-1 therapy, compared to 7.5% in the sham-treatment group. However, results were affected by variability at one trial site.

### What is the current stock price and ticker for Fractyl Health?

Fractyl Health trades on the NASDAQ under the ticker GUTS. The stock is currently priced at $1.38 per share, down 10.97% today.